- Home
- RYTM vs CHH Comparison
RYTM vs CHH Comparison
Compare RYTM & CHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- CHH
- Stock Information
- Founded
- RYTM 2008
- CHH 1939
- Country
- RYTM United States
- CHH United States
- Employees
- RYTM N/A
- CHH N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- CHH Hotels/Resorts
- Sector
- RYTM Health Care
- CHH Consumer Discretionary
- Exchange
- RYTM Nasdaq
- CHH Nasdaq
- Market Cap
- RYTM 5.9B
- CHH 6.1B
- IPO Year
- RYTM 2017
- CHH 1997
- Fundamental
- Price
- RYTM $88.64
- CHH $135.87
- Analyst Decision
- RYTM Strong Buy
- CHH Hold
- Analyst Count
- RYTM 13
- CHH 14
- Target Price
- RYTM $89.77
- CHH $135.14
- AVG Volume (30 Days)
- RYTM 1.0M
- CHH 399.1K
- Earning Date
- RYTM 08-05-2025
- CHH 08-06-2025
- Dividend Yield
- RYTM N/A
- CHH 0.86%
- EPS Growth
- RYTM N/A
- CHH 40.19
- EPS
- RYTM N/A
- CHH 6.57
- Revenue
- RYTM $136,863,000.00
- CHH $797,663,000.00
- Revenue This Year
- RYTM $37.47
- CHH $103.24
- Revenue Next Year
- RYTM $71.16
- CHH $3.42
- P/E Ratio
- RYTM N/A
- CHH $20.36
- Revenue Growth
- RYTM 48.88
- CHH N/A
- 52 Week Low
- RYTM $40.61
- CHH $116.20
- 52 Week High
- RYTM $94.80
- CHH $157.86
- Technical
- Relative Strength Index (RSI)
- RYTM 71.18
- CHH 55.00
- Support Level
- RYTM $87.86
- CHH $129.60
- Resistance Level
- RYTM $92.14
- CHH $133.44
- Average True Range (ATR)
- RYTM 3.57
- CHH 2.43
- MACD
- RYTM 1.01
- CHH -0.13
- Stochastic Oscillator
- RYTM 77.38
- CHH 41.79
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About CHH Choice Hotels International Inc.
As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.